



MEDICAL INSIGHT<sup>®</sup>

Global Facial Injectables Market Study

November 2017

## i. Methodology

This Facial Injectables Mini Report was compiled from a wide variety of public and proprietary sources. Information was cross-checked against other data, using Medical Insight's proprietary forecasting models, and synthesized into both qualitative and quantitative analyses and projections.

Public sources that were utilized include:

- articles in trade publications, medical journals and regulatory documents
- articles in consumer magazines and newspapers
- company news releases, website information, patent documents, marketing materials and financial filings
- information from trade associations

Proprietary sources that were utilized include:

- Medical Insight's extensive database of industry and product information
- Medical Insight survey data
- industry analyst reports
- exclusive interviews with, and feedback from company executives, researchers, sales representatives, physicians, patients, consultants and other industry experts

## **ii. New in November 2017**

This mini report represents the 15th edition of Medical Insight, Inc.'s Facial Injectables mini-report series. Like its predecessor, which was issued in November 2016, this report contains the latest industry news and updated market forecasts, which take into account recent technology, product, company, regulatory and other developments, as well as an in-depth analysis of the competitive positions of key players selling to both core and non-core aesthetic practices.

In addition to updated qualitative and quantitative product, manufacturer and market information, this report also includes new profiles on Asian suppliers of neurotoxins and dermal fillers.

### iii. Disclaimer

Information in this study has been obtained by Medical Insight, Inc. (Irvine, Calif.), from sources believed to be reliable. While Medical Insight believes the data provided herein to be accurate, no expressed or implied guarantees regarding accuracy or adequacy are made. Product and corporate data can change very quickly and without notice. The interested reader is encouraged to contact manufacturers directly.

This study is not intended as a substitute for proper due diligence. Although an attempt has been made to provide thorough coverage of the subject matter of this report, no guarantees regarding completeness or thoroughness are made. Medical Insight is not responsible for any errors, omissions or results obtained from use of information provided herein.

Any use that a reader makes of this report or any reliance on or decisions to be made based on it are the sole responsibility of such reader. Medical Insight accepts no responsibility for damages, if any, suffered by any reader as a result of decisions or actions taken based on this study.

Medical Insight, Inc., reserves all rights to this copyrighted document. This study is protected by U.S. Copyright Law; Copyright 2017 Medical Insight, Inc. Unauthorized reproduction is strictly forbidden by law. This report may not be reproduced in part or in whole without written consent of a duly authorized officer of Medical Insight. Multiple copies of this report can be obtained at a nominal cost by contacting the publisher.

Medical Insight, Inc.  
36 Discovery, Ste. 170  
Irvine, CA 92618 USA  
+1 949-830-5409 telephone  
+1 949-830-8944 facsimile  
Email: [mmoretti@miinews.com](mailto:mmoretti@miinews.com)

# M.I.I Professional Biography

Michael Moretti  
President  
Medical Insight, Inc.

Michael Moretti has served as a medical industry analyst and strategic advisor for more than 25 years. As an industry consultant, Mr. Moretti specializes in strategic business development projects and high-growth, emerging market segments. He provides custom reports and confidential market studies for a variety of clients, including global medical and pharmaceutical companies.

In 1993, Mr. Moretti founded Medical Insight, Inc., the leader in focused aesthetic market research offering comprehensive data on procedure volume and growth, revenue forecasts and new product introductions. Under Mr. Moretti's leadership, Medical Insight publishes global market studies and forecasts for major industry sectors such as facial injectables, cosmeceuticals, body shaping procedures, skin rejuvenation technologies and home-use aesthetic products. Medical Insight also sponsors executive business forums to address scientific developments and market trends for the investment community.

Mr. Moretti is the founder of *Aesthetic TV*<sup>®</sup>, the first and only one-stop online resource for current, reliable information about cosmetic and anti-aging treatments. *Aesthetic TV* offers expert advice for consumers via interviews with the top physicians in the field, and unprecedented access to the latest beauty-enhancing procedures and products created specifically to help people look and feel their absolute best.

Mr. Moretti is also founder and publisher of *THE Aesthetic Guide*<sup>®</sup> – a digital and print publication from Medical Insight featuring in-depth reports on new products, procedures and trends, reaching over 70,000 physicians, industry executives and investment analyst subscribers globally. Special editions of *THE Aesthetic Guide* address the European market and the Asian markets.

In 2007, Mr. Moretti debuted *THE Aesthetic Show*<sup>™</sup>, the first multidisciplinary annual business to business trade show that brings thousands of the highest profile physicians and medical professionals together in Las Vegas to learn about the newest aesthetic procedures, products and technologies in a dynamic, interactive, educational format. For more information please visit: [www.miinews.com](http://www.miinews.com).

#### Contact Information:

Michael Moretti  
Medical Insight, Inc.  
36 Discovery, Ste. 170  
Irvine, CA 92618 USA  
+1 (949) 830-5409 telephone  
+1 (949) 830-8944 facsimile  
Email: [mmoretti@miinews.com](mailto:mmoretti@miinews.com)  
Or visit the Medical Insight website at: [www.miinews.com](http://www.miinews.com)

<b>M.I.I</b>		<b>Table of Contents</b>	
<b>Disclaimer</b>		<b>4</b>	
<b>Biography</b>		<b>5</b>	
<b>Table of Contents</b>		<b>6</b>	
<b>Table of Exhibits</b>		<b>9</b>	
<b>1.0</b>	<b>Executive Summary</b>	<b>11</b>	
<b>2.0</b>	<b>Background</b>	<b>12</b>	
2.1	Neurotoxins	<b>13</b>	
	2.1.1 Overview of Condition and Treatment	<b>13</b>	
	2.1.2 Competitive Advantage	<b>16</b>	
	2.1.3 Product Descriptions and Results	<b>17</b>	
	2.1.3.1 BTX-A and BTX-B	<b>18</b>	
2.2	Dermal Fillers	<b>20</b>	
	2.2.1 Overview of Condition and Treatment	<b>20</b>	
	2.2.2 Competitive Advantage	<b>22</b>	
	2.2.3 Product Descriptions and Results	<b>24</b>	
<b>3.0</b>	<b>Market Forecasts</b>	<b>27</b>	
3.1	Product Sales	<b>29</b>	
	3.1.1 Neurotoxins	<b>29</b>	
	3.1.2 Dermal Fillers	<b>40</b>	
3.2	Procedure Volume Estimates	<b>51</b>	
	3.2.1 Neurotoxins	<b>51</b>	
	3.2.2 Dermal Fillers	<b>57</b>	
3.3	Competitive Analysis and Market Share	<b>63</b>	
	3.3.1 Neurotoxins	<b>63</b>	
	3.3.2 Dermal Fillers	<b>65</b>	
<b>4.0</b>	<b>Supplier Profiles</b>	<b>67</b>	
4.1	Adoderm	<b>67</b>	
4.2	Allergan	<b>68</b>	
4.3	Bellus Medical	<b>75</b>	
4.4	Biologica Technologies	<b>76</b>	

4.5	Bloomage	<b>76</b>
4.6	CM Aesthetic	<b>77</b>
4.7	Contura / Specialty Euro Pharma	<b>77</b>
4.8	CosmoFrance	<b>78</b>
4.9	Cosmoscience	<b>79</b>
4.10	CROMA-PHARMA	<b>79</b>
4.11	Daewoong Pharmaceutical	<b>81</b>
4.12	Eclipse Aesthetics	<b>82</b>
4.13	Laboratories Filorga	<b>82</b>
4.14	Galderma	<b>83</b>
4.15	Hangzhou Gallop Biological Products	<b>87</b>
4.16	Hangzhou Sinclean Medical Products Co., Ltd.	<b>88</b>
4.17	Harvest Technologies	<b>88</b>
4.18	Healeon Medical	<b>89</b>
4.19	HuGel	<b>90</b>
4.20	IBSA Farmaceutici Italia	<b>90</b>
4.21	Ipsen	<b>91</b>
4.22	Kaylight	<b>91</b>
4.23	Lanzhou Institute	<b>93</b>
4.24	LG Life Sciences	<b>94</b>
4.25	Laboratories MATEXLAB	<b>94</b>
4.26	Medytox	<b>95</b>
4.27	Merz	<b>96</b>
4.28	mesoestetic	<b>99</b>
4.29	NovoNexus	<b>99</b>
4.30	O'Meiye Group	<b>100</b>
4.31	Procytech/The Cell Bio-Tech (China) Co.	<b>100</b>
4.32	Prollenium Medical Technologies	<b>100</b>
4.33	RegenLab	<b>101</b>
4.34	Regenyal	<b>101</b>
4.35	Revance	<b>102</b>
4.36	Revitacare	<b>104</b>
4.37	SBS-Med	<b>105</b>

4.38	Sinclair Pharmaceuticals	<b>105</b>
4.39	Suiselle	<b>107</b>
4.40	Suneva Medical	<b>107</b>
4.41	Teoxane	<b>108</b>
4.42	Vias Partners	<b>110</b>
4.43	Laboratories Vivacy	<b>110</b>
4.44	Zimmer MedizinSysteme	<b>111</b>



# M.I.I. Table Of Exhibits

Table 1: Leading Neurotoxins	17
Table 2: Leading Dermal Fillers	24
Table 3: Characteristics of Selected Dermal Fillers	26
Table 4: Worldwide Projected Dollar Sales for Top Suppliers of Leading Neurotoxins	29
Figure 1: Worldwide Sales Growth of Neurotoxins	30
Table 5: North American Projected Dollar Sales of Neurotoxins for Top Suppliers	31
Figure 2: North American Sales Growth of Neurotoxins	32
Table 6: European Projected Dollar Sales of Neurotoxins for Top Suppliers	33
Figure 3: European Sales Growth of Neurotoxins	34
Table 7: Asian Projected Dollar Sales of Neurotoxins for Top Suppliers	35
Figure 4: Asian Sales Growth of Neurotoxins	36
Table 8: Latin American Projected Dollar Sales of Neurotoxins for Top Suppliers	37
Figure 5: Latin American Sales Growth of Neurotoxins	38
Figure 6: Dollar Sales Growth of Neurotoxins by Region	39
Table 9: Worldwide Projected Dollar Sales for Top Suppliers of Leading Dermal Fillers	40
Figure 7: Worldwide Sales Growth of Dermal Fillers	41
Table 10: North American Projected Dollar Sales of Dermal Fillers for Top Suppliers	42
Figure 8: North American Sales Growth of Dermal Fillers	43
Table 11: European Projected Worldwide Dollar Sales of Dermal Fillers for Top Suppliers	44
Figure 9: European Sales Growth of Dermal Fillers	45
Table 12: Asian Projected Dollar Sales of Dermal Fillers for Top Suppliers	46
Figure 10: Asian Sales Growth of Dermal Fillers	47
Table 13: Latin American Projected Dollar Sales of Dermal Fillers for Top Suppliers	48
Figure 11: Latin American Sales Growth of Dermal Fillers	49
Figure 12: Dollar Sales of Dermal Fillers by Region	50
Table 14: Worldwide Procedure Volume for Neurotoxins	51
Figure 13: Worldwide Procedure Fees for Neurotoxins	52

Figure 14: Worldwide Procedure Volume for Neurotoxins by Region	53
Figure 15: Worldwide Procedure Fees for Neurotoxins by Region	54
Table 15: Worldwide Procedure Volume for Dermal Fillers	55
Figure 16: Average Number of Weekly Neurotoxin Patients	55
Figure 17: Average Charge for a Single Neurotoxin Injection (single Tx session)	56
Figure 18: Worldwide Procedure Fees for Dermal Fillers	56
Figure 19: Worldwide Procedure Volume for Dermal Fillers by Region	57
Figure 20: Worldwide Procedure Fees for Dermal Fillers by Region	58
Figure 21: Average Charge of Weekly Dermal Filler Patients	61
Figure 22: Average Charge for a Single Dermal Filler Injection (single Tx session)	62
Table 16: Worldwide Market Shares for Top Neurotoxin Suppliers	59
Figure 23: Change in Market Shares of Top Neurotoxin Suppliers	60
Table 17: Market Shares of Top Dermal Filler Suppliers	61
Figure 24: Change in Market Shares of Top Dermal Filler Suppliers	62
Figure 25: BOTOX Injection Points	65
Figure 26: BOTOX Injection Points for Lateral Canthal Lines	66

<b>Section</b>	<b>Executive Summary</b>
<b>1</b>	

The market for facial injectables continues to grow strongly, although gains through the foreseeable future will be pressured by rising competition and industry consolidation. In 2016, the total global market for all injectables approached \$3.9 billion.

Through the forecast period, total global sales of cosmetic neurotoxins are expected to rise by 12.0% per year to reach close to \$3.2 billion in 2021. This is higher than the 10.2% CAGR predicted in the prior edition of this report. Additionally, through 2021, worldwide sales of dermal fillers are expected to expand by 11.9% per year, on average, from \$2.0 billion in 2016 to \$3.6 billion in 2021. This is higher than the rate of growth predicted in the prior edition of this report.

Close to 12 million cosmetic neurotoxin procedures were performed worldwide in 2016. This includes BOTOX, as well as injections with other neurotoxins such as Ipsen / Galderma's Dysport, Merz's Xeomin and Lanzhou Institute's Hengli. By 2021, the total number of cosmetic neurotoxin procedures (excluding injections for the treatment of migraines, hyperhidrosis, etc.) is expected to reach close to 19 million treatments, with strong international growth. Total procedure volume for dermal fillers in 2016 was estimated at nearly 6.8 million treatments. Through 2021, procedure volume will expand to nearly 10 million injections. For both neurotoxins and dermal fillers, average treatment frequency will rise relatively slowly.

**Figure 23**  
**Change in Market Shares of Top**  
**Neurotoxin Suppliers,**  
**2016 – 2021**  
**November 2017**

